MDA-TIL

autologous tumor-infiltrating lymphocytes · MD Anderson Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MDA-TIL, covering 2025-04-17 to 2025-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma [Phase 2]

See pricing